TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04298775

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia with morphine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia without morphine + peripheral nerve block
Study: NCT02069470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuing Medical Education
Description: 3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
Study: NCT03166566

Intervention type: DEVICE
Group type: OTHER
Intervention: Laminar drainage implant surgery.
Description: A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.
Study: NCT02718742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00344721

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid supplement
Description: Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
Study: NCT03913052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular Viscosupplement Application
Description: Injection containing hyaluronic acid, chondroitin sulphate and glucosamine is performed once when the knee joint was in the supine position and the knee is in the extension.
Study: NCT01301443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subretinally injected RetinoStat
Description: Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
Study: NCT01911442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 20 mg daily
Description: Lurasidone 20 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 60 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00808236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RhinoChill
Description: Nasal catheters are placed and cooling is begun during the resuscitation attempt

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Advanced cardiac life support according to American Heart Association \& European Resuscitation Council 2005 Guidelines
Study: NCT00362934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate / simvastatin
Description: Combination of fenofibrate and simvastatin 20 mg and 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10 mg and 20mg
Study: NCT02153528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: double rimfampicin
Description: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard TB treatment
Description: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Study: NCT01908270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study: NCT02336659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exendin 9-39
Description: Exendin 9-39 is a specific GLP-1 receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exendin 9-39
Description: Exendin 9-39 is a specific GLP-1 receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: DPP-4 Inhibition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: DPP-4 Inhibition

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT00141024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1043
Description: Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1043
Description: Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1043
Description: Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1043
Description: Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1090
Description: DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1090
Description: DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
Study: NCT03853681

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: additional blood sampling
Description: additional blood sampling
Study: NCT03436459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy
Description: shock wave therapy once a week for three weeks, total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute using a BTL-6000 SWT Topline Power® device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: LLLT once a day for three weeks (altogether 15 working days) using a PR999 4W scanning laser device; around trigger points with 3 J/cm2, power 800 mW, frequency 2000Hz, on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot
Study: NCT01576770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lidocaine/tetracaine transdermal patch (NDC 43469-864-01)
Description: 70 mg lidocaine / 70 mg tetracaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gebauer's Ethyl Chloride
Description: Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
Study: NCT02221531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin Short-infusion
Description: Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)

Intervention type: DRUG
Group type: OTHER
Intervention: Carbetocin Bolus application
Description: Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
Study: NCT02386280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for Change of Parenting Styles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psicoeducation

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psicoeducation
Study: NCT04899271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: 400 mg b.i.d. for 13 cycles of 14 days on/14 days off

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally with the same scheme of administration of LDX to preserve blinding
Study: NCT00455689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women.
Study: NCT06078423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose program
Description: Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 4-dose program
Description: Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 5-dose program
Description: Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 4-dose program
Description: Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
Study: NCT02534688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG-IUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA
Study: NCT04688775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab - concentrate for solution for infusion, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab - concentrate for solution for infusion, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
Study: NCT02847195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pupillometry
Description: This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
Study: NCT01102075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture procedure
Description: We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
Study: NCT03675035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: Reduction of the gastro-jejunal anastomosis through sutures
Study: NCT03216096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ophthalmic solution and 3% DE-089 ophthalmic solution
Description: Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
Study: NCT03495258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clarion Evolve Laser Vaporization System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Olympus TURis Plasma Vaporization
Study: NCT03186690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Study: NCT01565915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perlane-L
Description: Perlane-L Injection in the midface

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-treatment
Description: Non-treatment Arm
Study: NCT00793260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Support
Description: The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual-Support
Description: Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
Study: NCT04101565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text4Father
Description: Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
Study: NCT02354222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Canagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02996188

Intervention type: PROCEDURE
Intervention: routine therapeutic paracentesis
Study: NCT02359630

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EasyTube
Description: Insertion for ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyTube
Description: Insertion for ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Insertion for ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Description: Insertion for ventilation
Study: NCT03803072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time restricted eating (TRE)
Description: Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.
Study: NCT00456105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician
Description: See Detailed Description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team
Description: See detailed description.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Subjects without diabetes will have their blood glucose levels monitored while in the hospital
Description: See detailed description.
Study: NCT04060420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive sexual and reproductive health services
Description: The intervention includes community-based and peer-led delivery of comprehensive sexual and reproductive health services and a Yathu Yathu prevention points card, which is a card that adolescents and young people can use to gain points for accessing services and use these points to redeem rewards.
Study: NCT03154814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: conventional CPB was applied without ulinastatin treatment
Study: NCT03509142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System
Description: Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Study: NCT01225731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Description: SC administration of tildrakizumab at assigned dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Description: SC administration of tildrakizumab at assigned dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Description: SC administration of tildrakizumab at assigned dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Description: SC administration of tildrakizumab at assigned dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Description: SC administration of tildrakizumab at assigned dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Description: SC administration of tildrakizumab at assigned dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Description: SC administration of tildrakizumab at assigned dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Description: SC administration of tildrakizumab at assigned dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration of Placebo
Study: NCT04586543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: 10 mg selegiline tablet per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
Study: NCT02266667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 NEMOST rods : bilateral vertebral-pelvic implantation
Description: Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 NEMOST rod :unilateral vertebral-pelvic implantation
Description: Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
Study: NCT04171479

Intervention type: DEVICE
Intervention: Epicardial mapping and/or ablation
Description: Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.

Intervention type: DEVICE
Intervention: Epicardial mapping and/or ablation
Description: Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.
Study: NCT01607424

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive remediation
Description: RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
Study: NCT01251848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitaxentan
Description: Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days